BPIQ Blog

Mar 28, 20192 min read

SUPN Reports Mixed Results in ADHD

SUPN reported mixed positive results today for its final phase 3 trial for SPN-812 in attention deficit hyperactivity disorder (ADHD).*...

Mar 26, 20191 min read

ALDX Presents Positive Ph3 Data in Allergic Conjunctivitis

Congrats to ALDX on strong Ph3 data in allergic conjunctivitis (AC) not only showing statistical significant area under curve for ocular...

Mar 17, 20192 min read

Imminent Key Cystic Fibrosis Read-Outs for Proteostatis

Proteostasis (PTI) is scheduled to release data from 4 early-phase trials in Cystic Fibrosis (CF) imminently (i.e. this quarter) for all...

Mar 14, 20191 min read

UROV's Vibegron Imminent Phase 3 Readout In Overactive Bladder Has a Good Chance of Success

Based on robust Ph2B and Ph3 (Japan) data in prior trials with similar design, it appears highly likely that UROV's Vibegron will meet...

Mar 12, 20191 min read

HRTX Opioid-Free Pain Med Candidate Continues to Impress

Yesterday, Heron (HRTX) reported additional data for its opioid-free pain med candidate HTX-011 in a post-surgery setting. In the latest...

Mar 8, 20193 min read

ARQL Surprises Investors with Clinical Trial Updates

ARQL pleasantly surprised investors yesterday on its quarterly call by giving two positive clinical trial updates. First, and most...

Jump start your biotech due diligence

Our platform helps you uncover your next biotech investment opportunity